Literature DB >> 4426702

Host defense mechanisms against infectious bovine rhinotracheitis virus: in vitro stimulation of sensitized lymphocytes by virus antigen.

B T Rouse, L A Babiuk.   

Abstract

Isolated peripheral blood lymphocytes (PBL) from cattle immunized or infected with infectious bovine rhinotracheitis (IBR) virus were cultured in vitro with ultraviolet light-inactivated IBR virus, and the degree of lymphocyte blastogenesis was quantitated by measurement of the uptake of [(3)H]thymidine into acid-insoluble material. Lymphocyte blastogenesis only occurred with PBL from immunized or infected animals. The optimal conditions for lymphocyte blastogenesis were defined. Blastogenesis was specific since cells from animals immunized against IBR failed to react with two other herpesvirus antigens tested, herpes simplex and equine rhinopneumonitis viruses. Blastogenesis could be prevented by reacting IBR antigen with IBR-specific antibody before adding to cultures, but incorporating IBR-specific antibody in the culture medium after adding free antigen failed to inhibit blastogenesis. With intranasally infected animals, lymphocyte blastogenesis was detectable after 5 days, reached peak levels between days 7 and 10, and then declined to low levels by day 19. In contrast, levels of neutralizing antibody were barely detectable on day 7 and reached maximal concentrations on day 19. The lymphocyte blastogenesis assay was emphasized as a convenient and useful in vitro correlate of cell-mediated immunity that should help define the role of cell-mediated immunity in immunity to herpesviruses.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4426702      PMCID: PMC423006          DOI: 10.1128/iai.10.4.681-687.1974

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Cell-to-cell transmission of herpes simplex virus in primary human amnion cells.

Authors:  R T Christian; P P Ludovici; W S Jeter
Journal:  Proc Soc Exp Biol Med       Date:  1971-12

Review 2.  Viral infections in man associated with acquired immunological deficiency states.

Authors:  T C Merigan; D A Stevens
Journal:  Fed Proc       Date:  1971 Nov-Dec

3.  Six years experience with herpes simplex virus in a children's home.

Authors:  T C Cesario; J D Poland; H Wulff; T D Chin; H A Wenner
Journal:  Am J Epidemiol       Date:  1969-11       Impact factor: 4.897

4.  Immunoglobulins in serum and nasal secretions following infection with type 1 parainfluenza virus and injection of inactivated vaccines.

Authors:  C B Smith; J A Bellanti; R M Chanock
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

5.  The response of ponies to Myxovirus influenzae A-equi 2. II. Immunoglobulin classes of antibody to the virus in serum and nasal secretions.

Authors:  B T Rouse; W J Ditchfield
Journal:  Can J Comp Med       Date:  1970-01

Review 6.  Equine influenza immunisation--the role of nasal antibody--a review.

Authors:  B T Rouse
Journal:  Aust Vet J       Date:  1971-04       Impact factor: 1.281

7.  Cellular immunity in host resistance to viral infections.

Authors:  L A Glasgow
Journal:  Arch Intern Med       Date:  1970-07

8.  In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus.

Authors:  G L Rosenberg; P A Farber; A L Notkins
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

9.  Prevention of cell-to-cell spread of herpes simplex virus by leukocytes.

Authors:  D L Lodmell; A Niwa; K Hayashi; A L Notkins
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

10.  Mechanisms of recovery from a generalized viral infection: mousepox. 3. Regression infectious foci.

Authors:  R V Blanden
Journal:  J Exp Med       Date:  1971-05-01       Impact factor: 14.307

View more
  27 in total

1.  Immune interferon production by lymphoid cells: role in the inhibition of herpesviruses.

Authors:  L A Babiuk; B T Rouse
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

2.  Comparison of the antiviral effects of 5-methoxymethyl-deoxyuridine with 5-iododeoxyuridine, cytosine arabinoside, and adenine arabinoside.

Authors:  L A Babiuk; B Meldrum; V S Gupta; B T Rouse
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

3.  Mechanisms of resistant of herpesviruses: comparison of the effectiveness of different cell types in mediating antibody-dependent cell-mediated cytotoxicity.

Authors:  A S Grewal; B T Rouse; L A Babiuk
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

4.  Cell mediated immunity in equine herpesvirus type 1 infection I. In vitro lymphocyte blastogenesis and serum neutralization antibody in normal parturient and aborting mares.

Authors:  S K Dutta; D L Campbell
Journal:  Can J Comp Med       Date:  1977-10

Review 5.  Mechanisms of recovery from Herpesvirus infections -a review.

Authors:  B T Rouse; L A Babiuk
Journal:  Can J Comp Med       Date:  1978-10

6.  Immune effector cell activity in canines: failure to demonstrate genetic restriction in direct antiviral cytotoxicity.

Authors:  C K Ho; L A Babiuk; B T Rouse
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

7.  Defense mechanisms against bovine herpesvirus: relationship of virus-host cell events to susceptibility to antibody-complement cell lysis.

Authors:  L A Babiuk; R C Wardley; B T Rouse
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

8.  Effect of anti-herpesvirus drugs on human and bovine lymphoid function in vitro.

Authors:  L A Babiuk; B T Rouse
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

9.  Investigation of porcine natural-killer cell activity with reference to African swine-fever virus infection.

Authors:  S G Norley; R C Wardley
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

10.  Experimental T-2 toxicosis in sheep.

Authors:  S C Friend; D S Hancock; H B Schiefer; L A Babiuk
Journal:  Can J Comp Med       Date:  1983-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.